Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for Immune Tolerance Induction in ITP
NCT06478537Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in immune thrombocytopenia (ITP), sponsored by Peking Union Medical College Hospital. Primary endpoint: Sustained response off treatment at 3 years. Started Jun 2024; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06478537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478537.